GH

Guardant Health Inc

Add to Watchlist

Advanced Chart

65.060

-1.45(-2.180%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

66.775

Open

66.100

VWAP

65.88

Vol

2.04M

Mkt Cap

8.11B

Low

64.320

Amount

134.24M

EV/EBITDA(TTM)

Total Shares

122.37M

8.78B

EV/OCF(TTM)

P/S(TTM)

9.93

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

252.99M

+24.34%

-0.461

-5.87%

250.45M

+24.1%

-0.479

-22.81%

235.59M

+23.04%

-0.490

+8.8%

Estimates Revision

The market is revising Upward the revenue expectations for Guardant Health, Inc. (GH) for FY2025, with the revenue forecasts being adjusted by 4.27% over the past three months. During the same period, the stock price has changed by 42.08%.

Revenue Estimates for FY2025

Revise Upward

+4.27%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-6.42%

In Past 3 Month

Stock Price

Go Up

+42.08%

In Past 3 Month

17 Analyst Rating

-6.55% Downside

Wall Street analysts forecast GH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GH is 60.80 USD with a low forecast of 46.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

16 Buy

1 Hold

0 Sell

Strong Buy

-6.55% Downside

Current: 65.060

Low

46.00

Averages

60.80

High

70.00

-6.55% Downside

Current: 65.060

Low

46.00

Averages

60.80

High

70.00

Mizuho

Anthony Petrone

Buy

Initiates

$55

2025-04-10

Reason

Mizuho

Anthony Petrone

Price Target

$55

2025-04-10

Initiates

Buy

Reason

Mizuho analyst Bradley Bowers initiated coverage of Guardant Health with an Outperform rating and $55 price target. The firm is bullish on Guardant given: Smart Liquid Biopsy as a differentiated platform versus tissue-based competition; near-term access to nearly $20B of Precision Oncology total addressable market; positive survey response for Guardant's Blood-based colorectal cancer test, and; cash flow/profitability expectations with upside from success of aforementioned products. The firm added that its price target is above peers but deserved given near-term inflection points in sales and profitability.

Barclays

Luke Sergott

Buy

Maintains

$60 → $55

2025-04-10

Reason

Barclays

Luke Sergott

Price Target

$60 → $55

2025-04-10

Maintains

Buy

Reason

Barclays lowered the firm's price target on Guardant Health to $55 from $60 and keeps an Overweight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.

Stephens & Co.

Mason Carrico

Buy

Reiterates

$55

2025-03-26

Reason

Stephens & Co.

Mason Carrico

Price Target

$55

2025-03-26

Reiterates

Buy

Reason

Morgan Stanley

Shannon O'Callaghan

Buy

Maintains

$42 → $52

2025-03-06

Reason

Morgan Stanley

Shannon O'Callaghan

Price Target

$42 → $52

2025-03-06

Maintains

Buy

Reason

Piper Sandler

David Westenberg

Buy

Maintains

$34 → $50

2025-02-26

Reason

Piper Sandler

David Westenberg

Price Target

$34 → $50

2025-02-26

Maintains

Buy

Reason

Piper Sandler analyst David Westenberg raised the firm's price target on Guardant Health to $50 from $34 following quarterly results. The firm keeps an Overweight rating on the shares.

Canaccord Genuity

Kyle Mikson

Strong Buy

Maintains

$42 → $60

2025-02-24

Reason

Canaccord Genuity

Kyle Mikson

Price Target

$42 → $60

2025-02-24

Maintains

Strong Buy

Reason

Canaccord analyst Kyle Mikson raised the firm's price target on Guardant Health to $60 from $42 and keeps a Buy rating on the shares. The firm said they remain bullish after a strong finish to 2024 and solid outlook for 2025 with multiplepotential catalysts. They raise their target on higher margins in their discount free cash flow due to average sellng price tailwinds.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Guardant Health Inc (GH.O) is -36.46, compared to its 5-year average forward P/E of -21.45. For a more detailed relative valuation and DCF analysis to assess Guardant Health Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-21.45

Current PE

-36.46

Overvalued PE

-4.32

Undervalued PE

-38.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-21.64

Current EV/EBITDA

-45.07

Overvalued EV/EBITDA

-6.72

Undervalued EV/EBITDA

-36.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

13.59

Current PS

8.28

Overvalued PS

25.55

Undervalued PS

1.63

Financials

Annual

Quarterly

FY2025Q2

YoY :

+30.95%

232.09M

Total Revenue

FY2025Q2

YoY :

+5.76%

-106.41M

Operating Profit

FY2025Q2

YoY :

-2.66%

-99.90M

Net Income after Tax

FY2025Q2

YoY :

-4.76%

-0.80

EPS - Diluted

FY2025Q2

YoY :

-33.45%

-65.93M

Free Cash Flow

FY2025Q2

YoY :

+9.93%

65.01

Gross Profit Margin - %

FY2025Q2

YoY :

-29.48%

-32.78

FCF Margin - %

FY2025Q2

YoY :

-25.68%

-43.04

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

5.2M

USD

3-6

Months

12.9M

USD

6-9

Months

170.4K

USD

0-12

Months

625.1K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

3.2M

Volume

6-9

Months

2.9M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

971.1K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

5.2M

USD

3-6

Months

12.9M

USD

6-9

Months

170.4K

USD

0-12

Months

625.1K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

GH News & Events

Events Timeline

2025-07-30 (ET)

2025-07-30

16:34:53

Guardant Health raises FY25 revenue view to $915M-$925M from $880M-$890M

2025-07-30

16:33:31

Guardant Health reports Q2 EPS (44c), consensus (51c)

2025-07-29 (ET)

2025-07-29

09:08:56

Guardant Health announces RADIOHEAD study validates Guardant Reveal use

News

9.0

09-02Newsfilter

Innovative Cancer Treatments Drive Regulatory Progress Amid Global Market Growth

5.0

08-26TipRanks

Cathie Wood Sells More Roku Shares, Invests $13M in CRISPR and Intellia

5.0

08-23TipRanks

Cathie Wood Divests Shopify and Coinbase Shares, Increases Investment in PagerDuty (PD), 8/23/25

People Also Watch

BBAR

Banco BBVA Argentina SA

Axsome Therapeutics Inc

Acushnet Holdings Corp

Franklin Electric Co Inc

FAQ

What is Guardant Health Inc (GH) stock price today?

The current price of GH is 65.06 USD — it has decreased -2.18 % in the last trading day.

GH

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

GH News & Events

Events Timeline

News

People Also Watch

FAQ

What is Guardant Health Inc (GH) stock price today?

What is Guardant Health Inc (GH)'s business?

What is the price predicton of GH Stock?

What is Guardant Health Inc (GH)'s revenue for the last quarter?

What is Guardant Health Inc (GH)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Guardant Health Inc (GH)'s fundamentals?

How many employees does Guardant Health Inc (GH). have?

What is Guardant Health Inc (GH) market cap?